VENUS REMEDIES Financial Statement Analysis
|
||
|
The Revenues of VENUS REMEDIES have increased by 8.27% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 7.25 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹601 Cr | ₹556 Cr | ₹600 Cr | ₹548 Cr | ₹339 Cr |
| Expenses | ₹542 Cr | ₹495 Cr | ₹538 Cr | ₹494 Cr | ₹299 Cr |
| Operating Profit (Excl OI) | ₹60 Cr | ₹60 Cr | ₹62 Cr | ₹54 Cr | ₹41 Cr |
| Other Income | ₹12 Cr | ₹10 Cr | ₹8.31 Cr | ₹20 Cr | ₹5.31 Cr |
| Interest | ₹0.09 Cr | ₹0.12 Cr | ₹0.48 Cr | ₹13 Cr | ₹13 Cr |
| Depreciation | ₹26 Cr | ₹32 Cr | ₹34 Cr | ₹35 Cr | ₹32 Cr |
| Profit Before Tax | ₹45 Cr | ₹38 Cr | ₹36 Cr | ₹49 Cr | ₹-8.04 Cr |
| Profit After Tax | ₹28 Cr | ₹27 Cr | ₹41 Cr | ₹62 Cr | ₹-10.00 Cr |
| Consolidated Net Profit | ₹28 Cr | ₹27 Cr | ₹41 Cr | ₹62 Cr | ₹-10.00 Cr |
| Earnings Per Share (Rs) | ₹21.31 | ₹19.87 | ₹30.47 | ₹50.04 | ₹-8.10 |
| PAT Margin (%) | 4.74 | 4.78 | 6.79 | 11.27 | -2.95 |
| ROE(%) | 6.01 | 5.90 | 9.85 | 17.40 | -3.05 |
| ROCE(%) | 8.67 | 7.72 | 7.89 | 12.37 | 0.90 |
| Total Debt/Equity(x) | 0.08 | 0.09 | 0.10 | 0.13 | 0.68 |
Key Financials |
||
| Market Cap | : | ₹ 410.9 Cr |
| Revenue (TTM) | : | ₹ 614.6 Cr |
| Net Profit(TTM) | : | ₹ 22.1 Cr |
| EPS (TTM) | : | ₹ 16.5 |
| P/E (TTM) | : | 18.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| VENUS REMEDIES | 5.3% | -10.7% | -19.6% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.3% | -4.8% | 45% |
| CIPLA | 2.1% | 3.8% | 24.5% |
| DR REDDYS LABORATORIES | -0.6% | -5.7% | 5.7% |
| ZYDUS LIFESCIENCES | 0.1% | -3.6% | 48.2% |
| DIVIS LABORATORIES | 0.5% | 6.4% | 58.2% |
| MANKIND PHARMA | -1.9% | 1.4% | 33.8% |
| TORRENT PHARMACEUTICALS | 1.8% | 3.6% | 53.3% |
| LUPIN | -2.7% | -7.1% | 60.8% |
VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]
| Y-o-Y | 8.27 % |
| 5 Yr CAGR | 15.38 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹601 Cr | 8.27 | |
| Mar2023 | ₹556 Cr | -7.44 | |
| Mar2022 | ₹600 Cr | 9.50 | |
| Mar2021 | ₹548 Cr | 61.53 | |
| Mar2020 | ₹339 Cr | - | |
VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]
| Y-o-Y | -0.71 % |
| 5 Yr CAGR | 9.92 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹60 Cr | -0.71 | |
| Mar2023 | ₹60 Cr | -3.36 | |
| Mar2022 | ₹62 Cr | 15.50 | |
| Mar2021 | ₹54 Cr | 31.75 | |
| Mar2020 | ₹41 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -8.33 % |
| 5 Yr CAGR | -4.73 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 9.91% | -8.33 | |
| Mar2023 | 10.81% | 4.44 | |
| Mar2022 | 10.35% | 5.50 | |
| Mar2021 | 9.81% | -18.45 | |
| Mar2020 | 12.03% | - | |
VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]
| Y-o-Y | 7.25 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹28 Cr | 7.25 | |
| Mar2023 | ₹27 Cr | -34.77 | |
| Mar2022 | ₹41 Cr | -34.07 | |
| Mar2021 | ₹62 Cr | Positive | |
| Mar2020 | ₹-10.00 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -0.84 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 4.74 % | -0.84 | |
| Mar2023 | 4.78 % | -29.60 | |
| Mar2022 | 6.79 % | -39.75 | |
| Mar2021 | 11.27 % | Positive | |
| Mar2020 | -2.95 % | - | |
VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]
| Y-o-Y | 7.25 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹21 | 7.25 | |
| Mar2023 | ₹20 | -34.79 | |
| Mar2022 | ₹30 | -39.11 | |
| Mar2021 | ₹50 | Positive | |
| Mar2020 | ₹-8.10 | - | |
VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]
| Y-o-Y | 12.31 % |
| 5 Yr CAGR | 76.17 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 8.67% | 12.31 | |
| Mar2023 | 7.72% | -2.15 | |
| Mar2022 | 7.89% | -36.22 | |
| Mar2021 | 12.37% | 1,274.44 | |
| Mar2020 | 0.9% | - | |
VENUS REMEDIES Share Price vs Sensex
| Current Share Price | : | ₹306.7 |
| Current MarketCap | : | ₹ 410.9 Cr |
| Updated EOD on | : | Nov 29,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | 5.3% |
-10.7% |
-19.6% |
| SENSEX | 0.9% |
-0.3% |
20.9% |
VENUS REMEDIES related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about VENUS REMEDIES Financials
How the annual revenues of VENUS REMEDIES have changed ?
The Revenues of VENUS REMEDIES have increased by 8.27% YoY .
How the Earnings per Share (EPS) of VENUS REMEDIES have changed?
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 7.25 % YoY .
Check out Intrinsic Value of Peers of VENUS REMEDIES
Compare Stock Analytics of Peers of VENUS REMEDIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
